More recently, the Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) trial also demonstrated the renal protective effects of a SGLT2 inhibitor for T2DM patients with nephropathy [13]. This evidence concerns the gene SLC5A2 and kidney disorder.